Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)

NCT01160094 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01160094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01160094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO)
Lead sponsor
Novartis
Phase
Observational
Overall status
Completed
Start date
February 28, 2010
Completion date
July 31, 2013
Enrollment
288 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cancer